Urgent.News

600+ sources. One page. See who else covered it.

Editions

Finance & Markets

Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3

For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Braveheart Bio priced its

We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.

This story

This is one outlet's version. Read the fullest account.

Read the original at endpoints.news →

More in Finance & Markets

More from Thursday 6 August →